Navigation Links
Arena Pharmaceuticals Announces Third Quarter 2010 Financial Results and Reviews Recent Developments
Date:11/9/2010

and activities thereunder; and Arena's focus, goals, strategy, research and development programs, and ability to develop compounds and commercialize drugs. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, top-line results are based on a preliminary analysis of then available data, and such findings and conclusions are subject to change following a more comprehensive review of the data; the risk that regulatory authorities may not find data and other information related to Arena's clinical trials and other studies meet safety or efficacy requirements or are otherwise sufficient for regulatory approval; the timing of regulatory review and approval is uncertain; Arena's response to the complete response letter for the lorcaserin NDA may not be submitted in a timely manner and/or the information provided in such response may not satisfy the FDA; the FDA may request additional information prior to approval; unexpected new data; risks related to commercializing new products; Arena's ability to obtain and defend its patents; the timing, success and cost of Arena's research and development programs; results of clinical trials and other studies are subject to different interpretations and may not be predictive of future results; clinical trials and other studies may not proceed at the time or in the manner Arena or others expect or at all; Arena's ability to obtain adequate funds; risks related to relying on collaborative agreements; the timing and receipt of payments and fees, if any, from Arena's collaborators; and satisfactory resolution of pending and any future litigation or other disagreements with others. Additional factors that could cause actual results to differ materially from those stated or implied by Are
'/>"/>
SOURCE Arena Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Arena Pharmaceuticals Provides Update on GPR119 Portfolio for Type 2 Diabetes
2. Endologix Announces Publication of Clinical Trial Results Supporting Anatomical Fixation with a Suprarenal Aortic Extension
3. Arena and Eisai Announce Upcoming Lorcaserin Presentations at Obesity 2010
4. Arena and Eisai Provide Update on Lorcaserin FDA Advisory Committee Meeting
5. Arena Pharmaceuticals to Host Conference Call and Webcast Following Lorcaserin FDA Advisory Committee Meeting
6. Arena Pharmaceuticals Submits New Drug Application to FDA for Lorcaserin for Weight Management
7. Published Data Demonstrate Arena Pharmaceuticals Lorcaserin Has Low Abuse Potential
8. Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments
9. Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Tuesday, November 10, 2009
10. Arena Pharmaceuticals Lorcaserin to be Featured in Multiple Presentations at Obesity 2009
11. Arena Pharmaceuticals Reports Positive, Highly Significant BLOSSOM Trial Results for Weight Management; NDA Submission on Track for December
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... , July 25, 2014  The Chemistry, ... Tobago Ministry of Health approved the introduction of ... increases the cure rate from Hepatitis C, and ... genotype 1 virus. Telaprevir is available in ... INCIVO®. Photo - http://www2.prnewswire.com.br/imgs/pub/2014-07-25/original/2026.jpg   ...
(Date:7/25/2014)... 25, 2014  Acsis Inc., the market leader ... solutions, has recently posted an article, "Future ... and future needs for companies, extended supply chain, ... chain model no longer work today.  The article ... growth of mobile technology, machine to machine (M2M) ...
(Date:7/25/2014)... 25, 2014 According to a ... and China Insulin Market (Rapid-Acting, Short-Acting, Intermediate-Acting, Long-Acting, Premixed, ... Growth, Trends and Forecast (Value and Volume), 2013 - ... 19.99 billion in 2012 and is expected to grow ... to reach USD 32.24 billion in 2019. ...
Breaking Medicine Technology:The Hepatitis C virus is the main cause of liver transplant in the world 2The Hepatitis C virus is the main cause of liver transplant in the world 3Acsis Addresses Questions on the Modern Supply Chain 2Global Insulin Market Expected to Reach USD 32.24 Billion Globally in 2019: Transparency Market Research 2Global Insulin Market Expected to Reach USD 32.24 Billion Globally in 2019: Transparency Market Research 3Global Insulin Market Expected to Reach USD 32.24 Billion Globally in 2019: Transparency Market Research 4
(Date:7/27/2014)... July 27, 2014 The European Agricultural ... in Europe with analysis and forecast of revenue. The ... from around $509.4 million in 2013 to $657.1 million ... to 2018. , Browse through the TOC of the ... of the in-depth analysis provided. It also provides a ...
(Date:7/27/2014)... 27, 2014 Metachromatic leukodystrophy (MLD, ... storage disease which is commonly listed in the ... sphingolipidoses as it affects the metabolism of sphingolipids. ... the fatty covering which acts as an insulator ... nervous systems. MLD involves cerebroside sulfate accumulation. Metachromatic ...
(Date:7/27/2014)... (PRWEB) July 27, 2014 One of the ... genomics products from the Asia Pacific (APAC) region. The Diagnostics ... to generate high demand for genomics solutions, thereby contributing to ... will grow at a CAGR of 11.21 percent over ... driver of the market is an increase in the demand ...
(Date:7/27/2014)... 2014 Alta Resources , a ... for Fortune 500 brands, announced today that it plans ... in Wisconsin, California, Florida and the Philippines. , A ... clients, which have seasonal ramp-ups that require additional staffing ... 2014 through February 2015. As more consumers become eligible ...
(Date:7/27/2014)... 27, 2014 Wright & Schulte LLC ... filed a GranuFlo lawsuit against Fresenius Medical Care ... over the recalled dialysis drugs GranuFlo and NaturaLyte. The ... by not disclosing the heart attack risks associated with ... Fresenius notified its own clinics, practitioners and physicians about ...
Breaking Medicine News(10 mins):Health News:Europe Agricultural Adjuvants Market is Expected to Reach $657.1 million in 2018 - New Report by MicroMarket Monitor 2Health News:Europe Agricultural Adjuvants Market is Expected to Reach $657.1 million in 2018 - New Report by MicroMarket Monitor 3Health News:Europe Agricultural Adjuvants Market is Expected to Reach $657.1 million in 2018 - New Report by MicroMarket Monitor 4Health News:Europe Agricultural Adjuvants Market is Expected to Reach $657.1 million in 2018 - New Report by MicroMarket Monitor 5Health News:Metachromatic Leukodystrophy Therapeutics Clinical Trials Market Review H2 2014 Report Available at LifeScienceIndustryResearch.com 2Health News:Metachromatic Leukodystrophy Therapeutics Clinical Trials Market Review H2 2014 Report Available at LifeScienceIndustryResearch.com 3Health News:Metachromatic Leukodystrophy Therapeutics Clinical Trials Market Review H2 2014 Report Available at LifeScienceIndustryResearch.com 4Health News:Metachromatic Leukodystrophy Therapeutics Clinical Trials Market Review H2 2014 Report Available at LifeScienceIndustryResearch.com 5Health News:Genomics, Single Nucleotide Polymorphism Genotyping and Analysis Market 2014 – 2018 in New Research Report at Sandlerresearch.org 2Health News:Genomics, Single Nucleotide Polymorphism Genotyping and Analysis Market 2014 – 2018 in New Research Report at Sandlerresearch.org 3Health News:Genomics, Single Nucleotide Polymorphism Genotyping and Analysis Market 2014 – 2018 in New Research Report at Sandlerresearch.org 4Health News:Genomics, Single Nucleotide Polymorphism Genotyping and Analysis Market 2014 – 2018 in New Research Report at Sandlerresearch.org 5Health News:Alta Resources to Fill Approximately 2,500 Positions 2Health News:Alta Resources to Fill Approximately 2,500 Positions 3Health News:Louisiana Files GranuFlo Lawsuit Against Fresenius Medical Care over Its Recalled GranuFlo and NaturaLyte Dialysis Drugs 2Health News:Louisiana Files GranuFlo Lawsuit Against Fresenius Medical Care over Its Recalled GranuFlo and NaturaLyte Dialysis Drugs 3Health News:Louisiana Files GranuFlo Lawsuit Against Fresenius Medical Care over Its Recalled GranuFlo and NaturaLyte Dialysis Drugs 4Health News:Louisiana Files GranuFlo Lawsuit Against Fresenius Medical Care over Its Recalled GranuFlo and NaturaLyte Dialysis Drugs 5
... of Chemicals, has shifted the burden or responsibility of handling ... would be bound by law to make use of only ... law aims to make chemicals used in all products ; ... ,The European Parliament has approved this legislation on ...
... plausible culprit for rendering sick nearly 260 Tewksbury students, ... stomach virus// has allegedly gripped several of the students ... not about to spare anyone- teachers, parents and siblings ... us to keep everything clean,” said Sue McLaughlin, co-chairwoman ...
... for ovarian cancer are at increased risk of a ... have high// levels of a binding protein that triggers ... of malignancy. ,“Now there’s the possibility that ... surgery might identify women most at risk for recurrence ...
... symptoms, including enlarged or painful breast tissue, but the ... Mayo Clinic Cancer Center. // Mammograms are used to ... very rare in males. ,Their study, presented Saturday, ... Antonio Breast Cancer Symposium, suggests physicians should reconsider ordering ...
... vaccine against HIV/AIDS, the 'social vaccine' of mass awareness needs ... a top UN official here said Saturday. // ... HIV/AIDS," said Peter Piot, executive director of United Nations Programme ... create a mass awareness to educate the people about the ...
... followed the discovery of neural stem cells and their potential ... spinal cord//, recent research identified “cancer stem cells,” a small ... cells comprising a malignant brain tumor. Theoretically, if these mother ... to sustain itself. On the other hand, if these cells ...
Cached Medicine News:Health News:'Clumping' Protein Linked to Return of Ovarian Cancer 2Health News:Use of Mammograms in Men 2Health News:Genes That Allow Brain Cancer-Causing Stem Cells to Resist Treatment Identified 2Health News:Genes That Allow Brain Cancer-Causing Stem Cells to Resist Treatment Identified 3
... 80 mm. Grooved buckle. Size: 2.3 x 4.0 ... original Scleral Sponge II line designed by Harvey ... closed cell sponge which is non-toxic and non-antigenic. ... scleral intrusion. These implants are packaged sterile and ...
For use with E5381 700 Circling Band (240 style)....
For use under curved implants. Indications: When additional buckling is required in the meridional direction. Overall length: 12.0 mm....
For use with E5381 600 Circling Band (40 style)....
Medicine Products: